The Ella Cancer Institute Inaugurated
The "Ella" Institute for Melanoma and Skin Cancer Treatment and Research has recently started to function within the framework of the Oncology Division and the Cancer Research Center at the Sheba Medical Center, Tel Hashomer
The Ella Institute inauguration ceremony took place on April 4, 2004 at the new Oncology Institute at the Sheba Medical Center.
The Ella Institute can now offer new treatment for patients diagnosed with Melanoma. This innovative treatment was developed in the United States at the National Cancer Institute (NCI), and is based on in vitro technology that initiates the reactivation and propagation of anti-cancer lymphocytes.
The Ella Institute (dedicated to the memory of Ella Lemelbaum (Loren) was established to carry out research and offer treatment for patients diagnosed with Melanoma and Skin Cancer. The Ella Institute will be a focus of clinical and scientific excellence in this field.
The Ella Institute, headed by Dr. Jacob Schechter, offers multi-disciplinary solutions for patients diagnosed with Melanoma and Skin Cancer, and includes laboratory research and progressive treatment and will function as a "clean laboratory", concentrating primarily on development and implementation of immunological treatment for Melanoma patients, and applied research in this field.
From a clinical aspect, the Institute includes a clinic offering a wide range of the most complex and progressive oncology services, including innovative surgical and diagnostic techniques.
The Institute enjoys a practical working relation with the most important and progressive cancer institute in the world, the NCI (The National Cancer Institute, USA).
Dr. Schechter explains: "Cooperation with the NCI forms a link between the Ella Institute and the most progressive Melanoma and Skin Cancer medical research and treatment platforms.
The Ella Institute can offer patients diagnosed with progressive stage Melanoma new hope by offering innovative treatment that is based on a method designed to produce lymphocyte cells found in cancer tumors. In a laboratory setting, an innovative technique is utilized to reactivate and induce propagation of these sparse and ineffective cells, after which the cells are reintroduced into the patient's system, where they effectively attack the cancer cells. The process of setting up the laboratory and activating the technology is now under way and will continue for a number of months.
